Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does METOCLOPRAMIDE Cause Malignant neoplasm progression? 19 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Malignant neoplasm progression have been filed in association with METOCLOPRAMIDE (metoclopramide hydrochloride). This represents 0.2% of all adverse event reports for METOCLOPRAMIDE.

19
Reports of Malignant neoplasm progression with METOCLOPRAMIDE
0.2%
of all METOCLOPRAMIDE reports
11
Deaths
11
Hospitalizations

How Dangerous Is Malignant neoplasm progression From METOCLOPRAMIDE?

Of the 19 reports, 11 (57.9%) resulted in death, 11 (57.9%) required hospitalization, and 2 (10.5%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for METOCLOPRAMIDE. However, 19 reports have been filed with the FAERS database.

What Other Side Effects Does METOCLOPRAMIDE Cause?

Nausea (1,080) Drug ineffective (927) Off label use (926) Drug hypersensitivity (751) Vomiting (672) Dyspnoea (525) Headache (499) Diarrhoea (481) Hypersensitivity (473) Tardive dyskinesia (465)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which METOCLOPRAMIDE Alternatives Have Lower Malignant neoplasm progression Risk?

METOCLOPRAMIDE vs METOLAZONE METOCLOPRAMIDE vs METOPIMAZINE METOCLOPRAMIDE vs METOPROLOL METOCLOPRAMIDE vs METRELEPTIN METOCLOPRAMIDE vs METRONIDAZOLE

Related Pages

METOCLOPRAMIDE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression METOCLOPRAMIDE Demographics